79311_Auto_Edited-check.docx

Interleukin-34 deficiency aggravates development of colitis and colitis-associated cancer in mice

Liu ZX *et al*. Interleukin-34 deficiency aggravates colitis and cancer

Abstract

BACKGROUND

Although expression of interleukin (IL)-34 is upregulated in active ulcerative colitis (UC), the molecular function and underlying mechanism are largely unclear.

AIM

To investigate the function of IL-34 in acute colitis, in a wound healing model and in colitis-associated cancer in IL-34-deficient mice.

METHODS

Colitis was induced by administration of dextran sodium sulfate (DSS), and carcinogenesis was induced by azoxymethane (AOM). Whether the impact of IL-34 on colitis was dependent on macrophages was validated by depletion of macrophages in a murine model. The association between IL-34 expression and epithelial proliferation was studied in patients with active UC.

RESULTS

IL-34 deficiency aggravated murine colitis in acute colitis and in wound healing phase. The effect of IL-34 on experimental colitis was not dependent on macrophage differentiation and polarization. IL-34-deficient mice developed more tumors than wild-type mice following administration of AOM and DSS. No significant difference was shown in degree of cellular differentiation in tumors between wild-type and IL-34-deficient mice. IL-34 was dramatically increased in the active UC patients as previously

reported. More importantly, expression of IL-34 was positively correlated with epithelial cell proliferation in patients with UC.

CONCLUSION

IL-34 deficiency exacerbates colonic inflammation and accelerates colitis-associated carcinogenesis in mice. It might be served as a potential therapeutic target in UC.

Key Words: Interleukin-34; Ulcerative colitis; Mucosal healing; Colitis-associated cancer; Macrophage; Murine model

Liu ZX, Chen WJ, Wang Y, Chen BQ, Liu YC, Cheng TC, Luo LL, Chen L, Ju LL, Liu Y, Li M, Feng N, Shao JG, Bian ZL. Interleukin-34 deficiency aggravates development of colitis and colitis-associated cancer in mice. *World J Gastroenterol* 2022; In press

Core Tip: This study highlights the role of interleukin (IL)-34 in acute experimental colitis and wound healing phase in mice. We found that IL-34 did not drive inflammatory response and tissue destruction in physiological conditions, but protects the host from inflammatory injury and reduces the risk of colitis-associated cancer. IL-34 might serve as a potential therapeutic target for inducing mucosal healing in treatment of ulcerative colitis (UC) and reducing colitis-associated cancer in UC.

INTRODUCTION

Ulcerative colitis (UC) is a chronic progressive recurrent intestinal inflammatory disorder characterized by bloody diarrhea and abdominal pain[1]. UC is an important promoter of colorectal cancer[2]. The exact pathogenesis of UC remains unclear. It is currently assumed that it involves immunological derangement of the gut microbiota in genetically predisposed individuals after exposure to environmental factors[1]. Cytokines exert multiple effects and participate in the pathogenesis of colitis[3].

Identification of distinctive cytokines involved in immunopathogenesis of UC has become a hot spot for the development of biological therapies[4]. Colony-stimulating factor-1 receptor (CSF-1R) signaling regulates intestinal and colon development, gut homeostasis and inflammatory reaction[5]. Interleukin (IL)-34 was discovered in 2008 as a specific ligand for CSF-1R independent of CSF-1[6,7]. Human IL-34 is a homodimeric glycoprotein that consists of 242 amino acids produced by various cell types including epithelial, endothelial and immune cells, and fibroblasts[8]. Secreted IL-34 binds to the extracellular domains of CSF-1R and protein-tyrosine phosphatase, the other receptor for IL-34, which is regulated by syndecan-1, which results in autophosphorylation of its intracellular tyrosine residues and activates several signaling pathways controlling cell biological function[8,9]. IL-34 functions as a pivotal regulator in cell differentiation, proliferation and survival in the mononuclear phagocyte system[10]. Additionally, IL-34 mediates the crosstalk between the innate and adaptive immune systems during inflammation[8,11].

Under normal circumstances, IL-34 is primarily expressed in a tissue-specific manner in keratinocytes and neurons[8]. In pathological status, the expression pattern is changed. Increased IL-34 expression positively associates with disease progression, severity and chronicity in autoimmune diseases such as rheumatoid arthritis and Sjogren's syndrome[12]. In contrast, IL-34 has demonstrated beneficial effects in other diseases. IL-34 has been identified as a new mediator to induce transplant tolerance by targeting suppressive T regulatory cells[13]. Therefore, the multiple function of IL-34 in different diseases is complex, disputable, and context-dependent[8].

The involvement of IL-34 in inflammatory bowel disease (IBD) has also drawn attention recently. Higher expression of IL-34 in human ileum compared with colon has been revealed[14]. In human and experimental colitis, the mRNA and protein level of IL-34 is markedly increased in inflamed mucosa compared to that in the matched normal mucosa and in healthy controls[14,15]. Recently, it has been proposed that IL-34 plays a prominent role in intestinal fibrogenesis *via* a p38 mitogen-activated-protein-kinase-dependent mechanism in Crohn's disease[16]. *In vitro,* tumor necrosis factor (TNF)-α

significantly upregulates expression of IL-34 in lamina propria mononuclear cells (LPMCs) *via* NF-kB signaling. Intriguingly, LPMCs treated with IL-34 increase expression of proinflammatory cytokines such as IL-6, TNF-α and chemokine CC ligand 20[15]. Accordingly, IL-34 neutralization decreases synthesis of TNF-α and IL-6 in IBD mucosal explants[15]. Therefore, it has been noted that IL-34 sustains gut inflammation *via* regulating positive feedback of proinflammatory cytokine production *in vitro*[8,15]. On the contrary, IL-34 has previously demonstrated immunosuppressive characteristics that contribute to inflammation improvement by inducing differentiation of monocytes into M2 phenotype[17]. M2 macrophages mediate immunotolerance and promote wound healing in experimental colitis *in vivo*[18,19]. IL-34 is upregulated in colon cancer and sustains the protumorigenic signals by inducing proliferation of cancer cells *via* extracellular signal-regulated kinase (ERK) 1/2 or cancer-associated fibroblasts[20,21]. Whether IL-34 is "friend or foe" in the pathogenesis of UC remains to be explored. In this study, we investigated the potential role of IL-34 in experimental colitis, colitis-associated carcinogenesis and UC.

MATERIALS AND METHODS

Animal experiment

IL-34-deficient mice were generated in C57BL/6J mice by using CRISPR/Cas9 technology (Beijing Cas Gene Biotech, Beijing, China). Gene targeting technology was applied to delete exons 3-5 in the *IL-34* gene and led to frameshift mutation of *IL-34* gene. IL-34-deficient and C57BL/6J wild-type mice were bred and maintained in a specific-pathogen-free animal facility in the Laboratory Animal Center of Nantong University. All animal experiments were approved by the Institutional Ethics Committee of Nantong University (Date: 21/12/2015, Number: S20151221-908).

Acute colitis was induced by oral administration of 3% (M/V) dextran sulfate sodium (DSS, MW: 36 000-50 000; MP Biologicals, LLC, California, United States) in drinking water for 7 d. The mice were killed to obtain colon tissues at the indicated time or until day 16 to record the mortality. The murine wound healing model was established by

oral administration of 3% DSS for 5 d and then switched to normal water for the following 5 d. The mice were killed on day 8 or 10. Colitis-associated cancer was induced by administration of the carcinogen azoxymethane (AOM; Sigma, Darmstadt, Germany) and repeated administration of DSS. The mice were given a single injection of AOM (10 mg/kg). Seven days later, mice were administrated 1.25% DSS (w/v) in drinking water for seven consecutive days, and fresh drinking water for 14 d. Seven days of DSS and 14 d of fresh water was repeated four times as a cycle[22]. The mice were killed, and the incidence rate of tumors was analyzed. Macrophage depletion from murine colons *in vivo* was performed as described previously[23]. In brief, 200 μL clodronate liposomes (Liposoma Research, Amsterdam, Netherlands) were intraperitoneally injected into mice 2 d prior to onset of experimental colitis and every 2 d during the process.

The percentage of body weight change of each mouse was recorded throughout the duration of DSS administration. Fresh feces from mice were collected for occult blood tests using a fecal occult blood kit (Nanjing Jiancheng Bioengineering, Jiangsu, China). The clinical score index of the murine model consisted of stool consistency and fecal occult blood, as previously described[24].

Human tissue

Human tissue specimens were obtained from 40 adult patients with active UC and 20 healthy controls during colonoscopy in Nantong Third People's Hospital Affiliated to Nantong University and Affiliated Hospital of Nantong University between January 2014 and August 2015. Histopathology was evaluated by an experienced pathologist. This study was approved by the Ethics Committee of Nantong Third People's Hospital Affiliated to Nantong University and Affiliated Hospital of Nantong University, and all people signed an informed consent form. All patients met the diagnostic criteria that were in line with the Consensus on Diagnosis and Management of Inflammatory Bowel Disease (2018, Beijing, China). The patients did not receive any therapy before

colonoscopy. More details on the patients' characteristics can be found in Supplementary Table 1.

Histopathology

The entire colon was harvested for measuring the length. The colon was washed in phosphate-buffer saline and fixed in 10% formaldehyde solution for 24 h. Hematoxylin-eosin (H&E) staining was performed on the tissue sections. The inflammatory score was as follows: Presence of occasional inflammatory cells in the lamina propria was scored as 0; increased numbers of inflammatory cells in the lamina propria was scored as 1; confluence of inflammatory cells extending into the submucosa was scored as 2; and transmural extension of the infiltrate was scored as 3. For tissue damage score, no mucosal damage was scored as 0; lymphoepithelial lesions were scored as 1; surface mucosal erosion or focal ulceration was scored as 2; and extensive mucosal damage and extension into deeper structures of the bowel wall was scored as 3. The combined histological score was calculated by inflammatory and tissue damage score, and ranged from 0 (no changes) to 6 (extensive infiltration and tissue damage).

Immunohistochemistry

The colonic tissues were sectioned into 4-μm slices following fixation with 10% formaldehyde and embedded in paraffin. Immunohistochemical staining was conducted as in our previous study[25]. Tissue slices were incubated with 3% H_2O_2 for 15 min after deparaffinization. Antigen was retrieved in citrate buffer (pH 6.0; Maxim Biotechnologies, Fuzhou, China) in a microwave for 10 min. Nonimmune 10% goat serum (Jackson ImmunoResearch Laboratories, West Grove, PA, United States) was used to block nonspecific reactions. The sections were incubated with primary antibodies: rabbit anti human/mouse IL34, 1:100 (Abcam, Cambridge, MA, United States); rabbit anti human/mouse Ki-67 antibody, 1:200 (Abcam); rabbit anti mouse CSF1-R 1:1000 (Abcam); and rabbit anti-mouse CD68, 1:100 (Boster Biological Technology, Wuhan, China) overnight at 4 °C. On the second day, the sections were

incubated with horseradish-peroxidase-conjugated secondary antibody (Shanghai Long Island Biotechnology, Shanghai, China) for 30 min at room temperature. 3, 3'-diaminobenzidine (Maxim Biotechnologies) was applied for 30 s. Hematoxylin was applied for contrast staining. Proliferation index of Ki-67 was defined as the percentage of Ki-67-positive cells in crypts (CK4) within the random visual scope. Positive index of CSF1-R was defined as the percentage of CSF1-R-positive cells in colonic mucosa within the random visual scope. All the tissue sections were analyzed by optical microscopy (IX73; Olympus, Tokyo, Japan) by experienced pathologists.

TUNEL assay

Colonic tissue sections were prepared as described above. Apoptosis was analyzed by fluorescence microscopy according to standard procedure using *in situ* cell death detection (Roche, Basel, Switzerland). Five randomly optical fields were chosen for further analysis.

RNA isolation and quantitative real-time PCR

Total RNA was extracted from the indicated murine colonic tissues by Trizol Reagent (TaKaRa Bio, Dalian, China). RNA samples were reverse-transcribed into cDNA with a PrimeScript™RT Master Mix kit (TaKaRa Bio). cDNA samples were detected using a SYBR®Premix Ex Taq™II kit (TaKaRa Bio) on CFX96 Real-Time PCR Detection System (Bio-Rad Laboratories, Hercules, CA, United States). PCR was performed at 95 °C for 30 s, and the samples were subjected to 40 cycles of amplification at 95 °C for 5 s and 60 °C for 30 s. Expression of target genes was normalized to β-actin. Gene expression was calculated using the $2^{-\Delta\Delta Ct}$ method. All the primers are listed in Supplementary Table 2.

Statistical analysis

Data are presented as mean ± SD. The difference between more than two groups was analyzed using one-way analysis of variance and comparison of two groups was carried out using a *t*-test. Differences in survival between two groups were analyzed by

Kaplan-Meier test. All statistical analyses were performed using GraphPad Prism 6.0 (San Diego, CA, United States). *P* < 0.05 was considered statistically significantly.

RESULTS

IL-34 *is elevated in colitis and colitis-related cancer*

We analyzed IL-34 mRNA expression in gastrointestinal mucosal epithelium in wild-type C57BL/6J mice. Expression of IL-34 was highest in the colon compared with other parts of the digestive tract (Figure 1A). We investigated expression of IL-34 in DSS-induced colitis and AOM-DSS-induced colitis-associated cancer in wild-type mice. Immunohistochemical staining of murine colon tissue revealed that expression of IL-34 was elevated in both acute and chronic colitis, with the highest expression in colitis-associated cancer (Figure 1B and C).

IL-34 *deficiency increases susceptibility to acute DSS-induced colitis*

To determine the role of IL-34 in murine acute experimental colitis, IL-34$^{-/-}$ and wild-type mice were fed with 3% DSS in drinking water for 7 d and then killed (Figure 2A). DSS-fed IL-34$^{-/-}$ mice showed significantly greater body weight loss compared to DSS-fed wild-type mice. The average weight loss in DSS-fed IL-34$^{-/-}$ mice was approximately double than that in the wild-type mice (Figure 2B). IL-34$^{-/-}$ mice displayed a significantly higher clinical score compared to wild-type mice (Figure 2C). Strikingly, the mortality of IL-34$^{-/-}$ mice was 100% (10/10), whereas only 20% (2/10) of the wild-type mice died during the experiment, as illustrated by Kaplan-Meier curves (Figure 2D, *P* < 0.001). Following DSS administration, IL-34$^{-/-}$ mice showed remarkably shorter colon compared to wild-type mice (4.83 cm ± 0.13 cm *vs* 6.27 cm ± 0.14 cm, *P* < 0.001), suggesting more severe colitis in IL-34$^{-/-}$ mice (Figure 2E and F). DSS-fed IL-34$^{-/-}$ mice exhibited more severe inflammation with ulceration and necrotic lesions compared to wild-type mice, while there was no difference in the wild-type or IL-34$^{-/-}$ mice fed with normal water. More inflammatory cells infiltrated the lamina propria and submucosa in DSS-fed IL-34$^{-/-}$ mice. More importantly, the normal tissue architecture damage was

more severe in DSS-fed IL-34$^{-/-}$ mice compared with wild-type mice (Figure 3A). Semiquantitative score of histopathology confirmed more severe colitis in DSS-fed IL-34$^{-/-}$ mice compared to DSS-fed wild-type mice (9.17 ± 0.31 *vs* 5.60 ± 1.10, $P < 0.001$) (Figure 3B). The expression of CD68, which serves as a characteristic marker for macrophages, was indistinguishable between IL-34$^{-/-}$ and wild-type mice untreated with DSS (Figure 3C and D). CD68 expression was significantly increased in DSS-fed IL-34$^{-/-}$ mice compared to DSS-fed wild-type controls (Figure 3C and D), which indicated worsening colitis. IL-1β, IL-23, and macrophage colony-stimulating factor levels were significantly upregulated in DSS-treated IL-34$^{-/-}$ mice compared to wild-type mice treated with DSS (Figure 3E).

IL-34 deficiency inhibits proliferation and promotes apoptosis of colonic epithelium in DSS-induced colitis

Prior to DSS administration, the levels of colonic epithelium proliferation and apoptosis were both comparable between wild-type and IL-34$^{-/-}$ mice (Figure 4A-D). A marked reduction in colonic epithelial cells stained positive for Ki-67 was detected in DSS-fed IL-34$^{-/-}$ mice compared to DSS-fed wild-type mice (Figure 4A and B). A marked increased in colonic epithelial cell apoptosis was noted in DSS-fed IL-34$^{-/-}$ mice compared to the DSS-fed wild-type mice (Figure 4C and D). We detected expression of three receptors of IL-34 in mouse colonic tissue by real-time quantitative PCR. In DSS-fed IL-34$^{-/-}$ mice, we only observed an increase in the expression of CSF1-R, but the other two receptors of IL34, ptprz1, and syndecan-1, did not change significantly (Figure 4E). By immunohistochemical staining of the mouse colonic tissues, we found that CSF1-R was expressed in epithelial and mesenchymal cells. Compared to the control group, the mice in the DSS-fed group showed an increasing positive index of CSF1-R. Expression of CSF1-R did not show a significant difference between IL-34$^{-/-}$ and wild-type mice untreated with DSS ($P > 0.05$, Figure 4F and G). DSS-fed IL-34$^{-/-}$ mice exhibited a higher index of CSF1-R positivity compared to DSS-fed wild-type mice ($P < 0.01$, Figure 4F and G). CSF1-R acts as a receptor for IL-34 and was compensatorily

increased when colitis developed and IL-34 was absent. The results were consistent with the results of quantitative real-time PCR of CSF1R.

Protective effect of IL-34 against acute DSS-induced colitis is not dependent on macrophages

Macrophages were increased in the IL-34[-/-] mice treated with 3% DSS compared with the wild-type mice. We investigated whether the protective effect of IL-34 in colitis was dependent on macrophages. It is known that IL-34 plays a role in macrophage polarization. We studied the potential role of IL-34 in macrophage polarization by examining the selected markers for M1 and M2 macrophages. Most importantly, there was no difference in the ratio of colonic M2/M1 macrophage markers between DSS-treated wild-type and IL-34[-/-] mice (Figure 5A). It was speculated that the effect of IL-34 on experimental colitis was not attributed to macrophage polarization. In order to confirm that the protective effect of IL-34 in colitis was not dependent on macrophages, we depleted macrophages by intraperitoneal injection of clodronate liposomes (Clo-lips) in IL-34[-/-] and wild-type mice (Figure 5B). The macrophage cell marker F4/80 was significantly reduced in colonic mucosa of mice treated with Clo-lips, which confirmed that the liposomes effectively depleted macrophages in the colon (Figure 5C). Despite macrophage depletion, DSS-fed IL-34[-/-] mice still showed significantly higher clinical score and shorter colon length compared with DSS-fed wild-type mice (Figure 5D-F). Similarly, the histopathological manifestation showed that colitis severity in DSS-fed IL-34[-/-] mice was more pronounced compared to that in DSS-fed wild-type mice (Figure 5G and H). The inflammatory cytokines remained significantly higher in colonic mucosa of DSS-fed IL-34[-/-] mice compared with DSS-fed wild-type mice (Figure 5I).

IL-34 deficiency delays mucosal healing in a murine model induced by DSS

IL-34[-/-] and wild-type mice were fed with 3% DSS for 5 d and then switched to normal water for the following 5 d to establish a mucosal healing model. The mice in both groups were killed on day 8 or 10 (Figure 6A). The body weight loss was significantly

greater in IL-34$^{-/-}$ mice compared to the wild-type control mice. The body weight increased quickly on day 8 in wild-type mice, while it did not recover until day 10 in IL-34$^{-/-}$ mice (Figure 6B). The clinical score was higher in IL-34$^{-/-}$ mice compared to wild-type mice from day 5. The clinical score decreased rapidly from day 7 in wild-type mice, while it was falling slowly from day 8 in IL-34$^{-/-}$ mice (Figure 6C). IL-34$^{-/-}$ mice showed remarkably shorter colon length compared to wild-type controls on day 8 (5.25 cm ± 0.32 cm vs 6.30 cm ± 0.25 cm, P < 0.01) and day 10 (5.03 cm ± 0.49 cm vs 7.30 cm ± 0.47 cm, P < 0.005) (Figure 6D and E). Histopathological analysis showed that IL-34$^{-/-}$ mice exhibited more severe inflammation and tissue damage compared to wild-type mice on days 8 and 10, respectively (Figure 6F). Semiquantitative scoring of histopathology showed that colitis severity in IL-34$^{-/-}$ mice was significantly higher than that in wild-type mice on day 8 (8.13 ± 0.66 vs 3.63 ± 0.58, P < 0.01) and day 10 (8.45 ± 0·61 vs 2.60 ± 0.58, P < 0.01), respectively (Figure 6G). The number of colonic epithelial cells positive for Ki-67 was markedly decreased in IL-34$^{-/-}$ mice compared to wild-type mice on days 8 and 10 (Figure 6H and I).

IL-34 deficiency promotes AOM/DSS-induced colitis-associated tumorigenesis

To investigate the role of IL-34 in colitis-associated tumorigenesis, wild-type and IL-34$^{-/-}$ mice were treated with AOM and DSS (Figure 7A). No wild-type mice died, whereas a mortality rate of 30% was noted in IL-34$^{-/-}$ mice (Figure 7B). More importantly, a marked difference in tumor number was observed between the two groups. IL-34$^{-/-}$ mice developed a greater number of colon tumors than wild-type mice (Figure 7C and D). Representative H&E staining of colitis-associated cancer in wild-type and IL-34$^{-/-}$ mice is shown in Figure 7E.

IL-34 expression was elevated in inflamed mucosa and was associated with colonic epithelium proliferation in UC patients

We investigated the IL-34 expression pattern and its relationship with colonic epithelium proliferation in active UC patients. There was no age or sex difference

between the groups (Supplementary Table 1). Consistent with previous studies, we also observed elevated expression of IL-34 in diseased mucosa of UC patients compared with the normal controls as detected by immunohistochemistry. Importantly, IL-34 was suspected to be predominantly expressed in the colonic stromal tissue (Figure 8A and B). Significantly enhanced colonic expression of proliferation index Ki-67 was detected in UC patients with higher IL-34 expression in colonic mucosa (Figure 8C). There was a positive correlation between IL-34 and Ki-67 expression in UC-inflamed mucosa with a correlation coefficient of 0.60 ($P < 0.0001$) (Figure 8D). No correlation was found between IL-34-positive and TUNEL-positive cells (data not shown).

DISCUSSION

Mucosal healing has become the goal of therapy because of its association with better prognosis and improved quality of life[26]. However, the underlying molecular mechanism is unclear. Here, we revealed that IL-34 deficiency strongly increased susceptibility to acute DSS-induced colitis and intestinal wounding. Additionally, IL-34 deficiency enhanced AOM/DSS-induced colitis-associated tumorigenesis. Different from the previous reports, our findings suggest the protective role of IL-34 in UC- and colitis-associated cancer and may help to establish a new potential approach for management of UC.

The IL-34 knockout mice used in our study facilitated us to illustrate the role of IL-34 in pathogenesis of UC. Prior to DSS administration, no difference in colon morphological and histological manifestations was observed between IL-34-deficient and wild-type control mice. The results suggest that IL-34 is dispensable for colon homoeostasis under steady state.

In past studies, overexpression of IL-34 stimulated by inflammatory cytokines augmented the production of proinflammatory cytokines *in vitro*, probably raising IL-34 as a pathogenic contributor to sustained colon inflammation[15]. However, the increased expression of IL-34 might be a consequence of inflammation as a protective mechanism rather than a disease cause[17]. Indeed, IL-34 transgenic mice do not display aggravating

inflammatory responses in the colon[27]. The precise mechanistic role of IL-34 during colon inflammation has not been clarified yet. Until now, there has been a lack of research on IL-34 involved in UC *in vivo*. A recent study has reported that IL-34 is critical for the suppressive function of CD4+ T regulatory cells, and its deficiency leads to increased susceptibility to autoimmunity[28]. We demonstrated for the first time that IL-34 deficiency exacerbates DSS-induced colitis during acute and delayed mucosal healing process and is associated with high colitis-related mortality. We assumed that significantly increased expression of IL-34 in mucosa from patients with active UC might act as an urgent requirement for alleviating inflammation and promoting mucosal healing. Our findings support the protective characteristic of IL-34 during DSS-induced colitis and early healing stage.

Macrophages are critical to mucosal homeostasis in orchestrating innate and adaptive immunity[29]. Depending on the local microenvironment, macrophages differentiated from the peripheral blood monocytes develop towards M1-like or M2-like phenotype macrophages[30]. M1 macrophages secreting proinflammatory cytokines such as TNF-α or IL-12 are considered to amplify the inflammatory response, whereas M2 macrophages producing anti-inflammatory mediators such transforming growth factor-β or IL-10 suppress the inflammatory response[30]. IL-34 has been identified to trigger CSF-1R signaling and induce macrophage differentiation to M2 phenotype *via* activation of the ERK1/2/AKT/AMPK signaling pathway[8], which contributes to mucosal homeostasis maintenance and tissue remodeling[18]. Regulation of M1 to M2 phenotype switch has been confirmed to promote the proliferative phase of wound healing and ameliorates DSS-induced colitis, indicating a possible role of IL-34 in alleviation of colonic inflammation[18,19]. In our study, IL-34-deficient mice treated with DSS presented with worse colitis with significant accumulation of macrophages compared to DSS-treated wild-type control mice. It is speculated that downregulation of the M1 to M2 macrophage phenotypic switch results in more severe colitis. However, M2/M1 macrophage ratio was not significantly decreased in DSS-treated IL-34-deficient mice. We subsequently depleted the macrophages in the murine colitis model by

administration of Clo-lips, which is a well-established method for macrophage depletion[31], showing that IL-34 deficiency aggravated murine colitis whether or not macrophages were depleted. Our results suggested that the protective effect of IL-34 on experimental colitis was not primarily dependent on macrophage polarization.

Mucosal healing largely relies on controlled colonic epithelial proliferation and apoptosis, which are manipulated by multiple growth factors, gut peptides, cytokines, as well as signaling pathways[26]. Given different DSS-induced injury levels in normal and IL-34-deficient colonic mucosa, we should be cautious to draw the conclusion that IL-34 deficiency inhibits the mucosal healing process *in vivo*. Based upon immunohistochemical staining, IL-34 was predominantly localized in the colon stromal tissue in our study. The specific cellular source of IL-34 needs to be further explored. In the acute colitis model, epithelial cell proliferation was inhibited but epithelial cell apoptosis was induced in IL-34$^{-/-}$ mice. CSF-1R was compensatorily increased in the IL-34$^{-/-}$ mice treated with DSS. Furthermore, it has been proved that IL-34 expression is positively correlated with epithelial proliferation in mucosal biopsies from UC patients. No correlation was shown between IL-34 expression level and apoptosis in UC patients. It is speculated that IL-34 might be produced from colon stromal tissue and promote colonic epithelial cell growth and wound closure by binding to CSF-1R in inflammatory conditions. Further studies are warranted to investigate the potential function of IL-34 in colonic epithelial cells.

Emerging data have demonstrated the multidimensional role of IL-34 in tumor progression and metastasis. The function of IL-34 in cancer may vary among different types of tumors[32]. A recent study on the relationship between IL-34 and gastric cancer proposed that the reduction of IL-34 in gastric cancer was inversely related to the degree of tumor differentiation and was closely related to the poor survival rate of patients[33]. However, the relationship of IL-34 to colorectal cancer remains controversial. It has been recently reported that IL-34 stimulates colorectal adenocarcinoma cell proliferation *via* an ERK1/2-dependent pathway. The connection between chronic colon inflammation and colitis-associated cancer has been documented

in UC patients. Repeated mucosal damage and repair in the inflamed microenvironment can result in uncontrolled epithelial cell proliferation and induce cancer events[34]. In a cohort study, Wang *et al*[35] showed that low expression of IL-34 is associated with poor survival in colorectal cancer. Accumulating evidence suggests that chronic inflammation enhances the development of colitis-associated cancer through multiple mechanisms, including oxidative stress, DNA damage, abnormal immune response, and gut microbiome dysbiosis[36]. In our study, tumor burden was markedly enhanced in IL-34$^{-/-}$ mice treated with AOM/DSS compared to wild-type control mice. We assumed that IL-34 deficiency worsened the colonic inflammation response and tissue damage, and thus sustained inflammatory injury increased the risk of colitis-associated cancer.

CONCLUSION

In summary, our work has highlighted the role of IL-34 during acute experimental colitis and wound healing. We found that IL-34 does not drive the inflammatory response and tissue destruction under physiological conditions, but protects the host from inflammatory injury and reduces the risk of colitis-associated cancer. IL-34 might serve as a potential therapeutic target for inducing mucosal healing in treatment for UC and reducing colitis-associated cancer in UC.

ARTICLE HIGHLIGHTS

Research background

The exact pathogenesis of ulcerative colitis (UC) remains unclear. Identification of distinctive cytokines involved in immunopathogenesis of UC has become a hot spot for the development of biological therapies. The expression of interleukin (IL)-34 is upregulated in active UC but the molecular function and underlying mechanism are largely unknown.

Research motivation

Whether IL-34 is a "friend or foe" in the pathogenesis of UC remains be explored. In this study, we investigated the potential role of IL-34 in experimental colitis, colitis-associated carcinogenesis and UC.

Research objectives

To investigate the function of IL-34 in acute colitis, in a wound healing model and in colitis-associated cancer, and the IL-34 expression pattern and its relationship with colonic epithelium proliferation in active UC patients.

Research methods

We conducted a controlled study using IL-34 knockout mice and wild-type mice (C57BL/6J). Colitis was induced by administration of dextran sodium sulfate, and carcinogenesis was induced by azoxymethane. Whether the impact of IL-34 on colitis was dependent on macrophages was validated by depletion of macrophages in a murine model. The association between IL-34 expression and epithelial cell proliferation was determined in patients with active UC.

Research results

IL-34 deficiency *in vivo* exacerbated colitis in mice during acute and wound healing phases and increased tumor susceptibility in the mouse colon. The effect was independent of macrophage differentiation and polarization. IL-34 was markedly increased in patients with active UC and the expression was positively correlated with epithelial cell proliferation in UC.

Research conclusions

IL-34 deficiency exacerbates colonic inflammation and accelerates colitis-associated carcinogenesis in mice.

Research perspectives

IL-34 might serve as a potential therapeutic target for inducing mucosal healing in treatment of UC and reducing colitis-associated cancer in UC.

Figure Legends

Figure 1 Interleukin-34 is elevated in colitis and colitis-related cancers. A: Interleukin-34 (IL-34) relative mRNA expression in stomach, jejunum, ileum and colon in wild-type mice (C57BL/6J) (n = 6); B and C: The dynamic of IL-34 expression in dextran sodium sulfate (DSS)-induced colitis and azoxymethane-DSS-induced colorectal cancer in wild-type mice (n = 6 per group); Representative IL-34 immunohistochemical staining for healthy control, acute colitis, chronic colitis and colorectal cancer mice (B); the percentage of IL-34-positive cells per high-power field were quantified in colonic tissue of four groups of mice (n = 6 per group) (C). AOM: Azoxymethane; CRC: Colorectal cancer; DSS: Dextran sodium sulfate; IL-34: Interleukin-34. Scale bars = 100 μm. Data depict the mean ± SD. ^aP < 0.05, ^bP < 0.01, ^cP < 0.005, ^dP < 0.001.

Figure 2 Interleukin-34 deficiency aggravates acute colitis induced by dextran sodium sulfate. A: Schematic of the design of acute dextran sodium sulfate (DSS)-induced colitis model. IL-34$^{-/-}$ and WT mice were fed with a 3% DSS solution in drinking water for 7 d and then sacrificed (n = 6 or 7 per group); B: Body weight was represented as a percentage of starting weight in IL-34$^{-/-}$ and WT mice after administration of 3% DSS (n = 6 or 7 per group); C: The clinical score of IL-34$^{-/-}$ and WT mice treated with 3% DSS (n = 6 or 7 per group). Data depict the mean ± SD; D: Kaplan-Meier survival curves were plotted in IL-34$^{-/-}$ and WT mice administrated with 3% DSS for 15 d (n = 10 per group); E and F: Colon length was measured in IL-34$^{-/-}$ and WT mice fed with 3% DSS for 7 d (n = 6 or 7 per group). DSS: Dextran sodium sulfate; IL-34: Interleukin-34; WT: Wild-type. Data depict the mean ± SD. ^aP < 0.05, ^bP < 0.01, ^cP < 0.005, ^dP < 0.001.

Figure 3 Interleukin-34 deficiency aggravates acute colitis and increase proinflammatory cytokines. A: Representative microscopic pictures of hematoxylin and eosin-stained colon sections of Interleukin-34 (IL-34)$^{-/-}$ and WT mice fed with 3% DSS for 7 d (n = 6 or 7 per group); B: Histological score for IL-34$^{-/-}$ and WT mice fed with 3% dextran sodium sulfate (DSS); C: Representative photomicrographs of macrophage staining in colon sections of IL-34$^{-/-}$ and WT mice treated with DSS; D: Statistical analysis of CD68-positive cells in IL-34$^{-/-}$ and WT mice treated with DSS; E: mRNA expression of proinflammatory cytokines including IL-1β, IL-10, IL-23, TNF-α and M-CSF in IL-34$^{-/-}$ and WT mice fed with 3% DSS. DSS: Dextran sodium sulfate; IL: Interleukin; M-CSF: Macrophage colony-stimulating factor; TNF-α: Tumor necrosis factor-α; WT: Wild-type. Scale bars = 100 μm. Data depict the mean ± SD. $^{b}P < 0.01$, $^{c}P < 0.005$, $^{d}P < 0.001$.

Figure 4 Interleukin-34 deficiency inhibits proliferation and promotes apoptosis of colonic epithelium in dextran sodium sulfate-induced colitis. A: Representative photomicrographs of Ki-67 immunohistochemical staining for colon sections of IL-34$^{-/-}$ and WT mice treated with dextran sodium sulfate (DSS); B: Percentage of proliferation marker Ki-67 per crypt; C and D: Representative microscopic pictures of TUNEL staining (C) and quantification of TUNEL-positive cells per field (D) in IL-34$^{-/-}$ and WT mice treated with DSS as before; E: mRNA expression of three receptors for IL-34 (CSF1R, ptprz1 and syndecan-1) was detected in IL-34$^{-/-}$ and WT mice treated with DSS (n = 6 or 7 per group); F and G: Representative photomicrographs of CSF1R immunohistochemical staining (F) and percentage of CSF1R-positive cells (G) in colon sections of IL-34$^{-/-}$ and WT mice treated with 3% DSS. CSF1R: Colony-stimulating factor-1 receptor; DSS: Dextran sodium sulfate; IL-34: Interleukin-34; WT: Wild-type. Scale bars = 100 μm. Data depict mean ± SD. $^{a}P < 0.05$, $^{b}P < 0.01$, $^{c}P < 0.005$.

Figure 5 Protective effect of interleukin-34 against acute dextran-sodium-sulfate-induced colitis is not dependent on macrophages. A: mRNA expression levels of M1 macrophage markers (iNOS, TNF-α and MCP-1) and M2 macrophage markers [ARG1, MRC2 (CD163)] in the colonic mucosa of IL-34$^{-/-}$ and WT mice treated with 3% DSS. M2/M1 ratio (CD163/iNOS) was calculated; B: Experimental design. To deplete macrophages, IL-34$^{-/-}$ and WT mice were treated with Clo-lips 2 d prior to 3% dextran sodium sulfate (DSS) administration and continuing once every 2 d until death (n = 4 per group); C: mRNA expression of macrophage cell marker (F4/80) was detected in colonic mucosa of WT mice treated with Clo-lips (n = 4 per group); D: E and F: Clinical score (F) and colon length (E and F) of IL-34$^{-/-}$ and WT mice treated with 3% DSS and Clo-lips (n = 4 per group); G and H: Representative microscopic pictures (G) and histological scores (H) of IL-34$^{-/-}$ and WT mice fed with 3% DSS and Clo-lips (n = 4 per group); I: mRNA expression of inflammatory cytokines was detected in IL-34$^{-/-}$ and WT mice treated with 3% DSS and Clo-lips (n = 4 per group). ARG1: Arginase; Clo-lip: Clodronate liposome; CSF1R: Colony-stimulating factor-1 receptor; DSS: Dextran sodium sulfate; IL-34: Interleukin-34; iNOS: Inducible nitric oxide synthase; MCP-1: Monocyte chemoattractant protein-1; MRC2: Mannose receptor C type 2; TNF-α: Tumor necrosis factor-α; WT: Wild-type. Scale bars = 200 µm. Data depict mean ± SD. $^{a}P < 0.05$, $^{b}P < 0.01$, $^{c}P < 0.005$.

Figure 6 Interleukin-34 deficiency delays the mucosal healing in murine model induced by dextran sodium sulfate. A: Establishing healing model chart. The Interleukin-34 (IL-34)$^{-/-}$ and WT mice were fed with 3% dextran sodium sulfate (DSS) for 5 d and switched to normal drinking water for the following 5 d. The mice in both groups were killed on day 8 or 10 (n = 4 or 5 per group); B and C: Body weight (B) and

clinical score (C) were determined daily in IL-34$^{-/-}$ and WT mice until day 10 (n = 4 or 5 per group); D and E:

F-I: The colon length was measured in IL-34$^{-/-}$ and WT mice on day 8 and 10, respectively (n = 4 or 5 per group). Representative microscopic pictures (F) and semiquantitative histological scores (G) of IL-34$^{-/-}$ and WT mice on day 8 and 10, respectively (n = 4 or 5 per group). Representative photomicrographs of Ki-67 immunohistochemical staining (H) and percentage of Ki-67-positive per crypt (I) in IL-34$^{-/-}$ and WT mice on day 8 and 10, respectively. DSS: Dextran sodium sulfate; IL-34: Interleukin-34; WT: Wild type. Scale bars = 200 μm. Data depict the mean ± SD. $^{a}P <$ 0.05, $^{b}P <$ 0.01, $^{c}P <$ 0.005.

Figure 7 Interleukin-34 deficiency promotes azoxymethane /dextran-sodium-sulfate-induced colitis-associated tumorigenesis. A: Experimental design was shown as diagram. WT and Interleukin-34 (IL-34)$^{-/-}$ mice were given a single injection of azoxymethane (AOM, 10 mg/kg). Seven days later, mice were treated with 1.25% dextran sodium sulfate (DSS) (w/v) in drinking water for seven consecutive days, and given fresh drinking water for 14 d. Seven days of DSS and 14 d of fresh water as a cycle, repeated four times; B: Kaplan-Meier survival curves were plotted in IL-34$^{-/-}$ and WT mice treated with AOM/DSS (n = 10 per group); C: Representative photo of colon and tumor number in colon in IL-34$^{-/-}$ and WT mice treated with AOM/DSS (n = 10 per group); D:

E: Representative hematoxylin and eosin-stained colon sections in IL-34$^{-/-}$ and WT mice treated with AOM/DSS (n = 10 per group). AOM: Azoxymethane; DSS: Dextran sodium sulfate; WT: Wild type. Bars: 1 mm (top) and 100 μm (bottom). Data depict mean ± SD. $^{a}P <$ 0.05.

Figure 8 Interleukin-34 expression was elevated in inflamed mucosa and associated with colonic epithelium proliferation in active ulcerative colitis. A: Representative

microscopic pictures of interleukin-34 (IL-34) immunohistochemical staining in colonic biopsies of healthy controls or individuals with active ulcerative colitis (UC); B: Percentage of IL-34-positive cells per high-power field were quantified in colonic biopsies of healthy controls (n = 20) and active UC patients (n = 40); C: Representative photomicrographs of immunostaining of Ki67 in colonic biopsies of active UC patients in IL-34 Lower expression and higher expression groups; D: Correlation analysis of colonic IL-34 expression and Ki 67-positive cells in active UC patients. IL-34: Interleukin-34; UC: Ulcerative colitis. Scale bar indicates 100 μm or 200 μm. [d]P < 0.001.

79311_Auto_Edited-check.docx

ORIGINALITY REPORT

28%

SIMILARITY INDEX

PRIMARY SOURCES

1	www.nature.com Internet	140 words —	2%
2	docplayer.net Internet	95 words —	1%
3	"Encyclopedia of Signaling Molecules", Springer Nature, 2018 Crossref	80 words —	1%
4	www.frontiersin.org Internet	69 words —	1%
5	www.wjgnet.com Internet	68 words —	1%
6	Yun Ge, Man Huang, Xiao-mei Zhu, Yong-ming Yao. "Biological functions and clinical implications of interleukin-34 in inflammatory diseases", Elsevier BV, 2020 Crossref	60 words —	1%
7	TAKAHIRO ISHIKURA. "Interleukin-18 overproduction exacerbates the development of colitis with markedly infiltrated macrophages in interleukin-18 transgenic mice", Journal of Gastroenterology and Hepatology, 8/2003 Crossref	56 words —	1%
8	bio-protocol.org Internet	56 words —	1%

9 tessera.spandidos-publications.com
Internet
51 words — 1%

10 etheses.whiterose.ac.uk
Internet
50 words — 1%

11 www.spandidos-publications.com
Internet
48 words — 1%

12 www.oncotarget.com
Internet
39 words — 1%

13 Hiroshi Katoh, Dingzhi Wang, Takiko Daikoku, Haiyan Sun, Sudhansu K. Dey, Raymond N. DuBois. "CXCR2-Expressing Myeloid-Derived Suppressor Cells Are Essential to Promote Colitis-Associated Tumorigenesis", Cancer Cell, 2013
Crossref
35 words — 1%

14 Muhammad Baghdadi, Hiraku Endo, Yoshino Tanaka, Haruka Wada, Ken-ichiro Seino. "Interleukin 34, from pathogenesis to clinical applications", Cytokine, 2017
Crossref
34 words — 1%

15 link.springer.com
Internet
33 words — < 1%

16 www.freepatentsonline.com
Internet
33 words — < 1%

17 Ido, Akio. "Hepatocyte growth factor ameliorates mucosal injuries leading to inhibition of colon cancer development in mice", Oncology Reports, 2011.
Crossref
30 words — < 1%

18 Muhammad Baghdadi, Yui Umeyama, Naoki Hama, Takuto Kobayashi, Nanumi Han, Haruka
28 words — < 1%

Wada, Ken-ichiro Seino. "Interleukin-34, a comprehensive review", Journal of Leukocyte Biology, 2018
Crossref

19   assets.researchsquare.com
      Internet
      27 words — < 1%

20   repository.dl.itc.u-tokyo.ac.jp
      Internet
      27 words — < 1%

21   downloads.hindawi.com
      Internet
      26 words — < 1%

22   Yu-Lin Xu, Hai-Lin Tang, Shi-Ying Zhu, Hao-Ran Peng, Zhong-Tian Qi, Wen Wang. "RIP3 deficiency exacerbates inflammation in dextran sodium sulfate-induced ulcerative colitis mice model", Cell Biochemistry and Function, 2017
      Crossref
      24 words — < 1%

23   core.ac.uk
      Internet
      24 words — < 1%

24   June-Chul Lee, Hae-Youn Lee, Tae Kang Kim, Min-Soo Kim et al. "Obesogenic diet-induced gut barrier dysfunction and pathobiont expansion aggravate experimental colitis", PLOS ONE, 2017
      Crossref
      23 words — < 1%

25   Maximilian Bockhorn. "Vascular endothelial growth factor does not improve liver regeneration and survival after 90% subtotal liver resection", Hepatology Research, 5/2007
      Crossref
      22 words — < 1%

26   Jie Zhang, Li Cen, Xiaofen Zhang, Chenxi Tang et al. "MPST deficiency promotes intestinal epithelial
      19 words — < 1%

cell apoptosis and aggravates inflammatory bowel disease via AKT", Redox Biology, 2022
Crossref

27 "Poster Presentations : Poster Presentations", Journal of Gastroenterology and Hepatology, 2013. 18 words — < 1%
Crossref

28 onlinelibrary.wiley.com 18 words — < 1%
Internet

29 Jiawei Li, Chao Qu, Fangfang Li, Yifang Chen, Jinjuan Zheng, Yao Xiao, Quanxin Jin, Guihua Jin, Xuezhu Huang, Dan Jin. "Inonotus obliquus Polysaccharide Ameliorates Azoxymethane/Dextran Sulfate Sodium-Induced Colitis-Associated Cancer in Mice via Activation of the NLRP3 Inflammasome", Frontiers in Pharmacology, 2021 16 words — < 1%
Crossref

30 Lin-Ling Ju, Lin Chen, Jun-Hong Li, Yi-Fan Wang, Ru-Jian Lu, Zhao-Lian Bian, Jian-Guo Shao. "Effect of NDC80 in human hepatocellular carcinoma", World Journal of Gastroenterology, 2017 16 words — < 1%
Crossref

31 Tiao-chun Cheng, Han Li, Xi Luo, Lin-ling Ju, Lin Chen, Jian-guo Shao, Yong-jun She, Min Li, Zhao-lian Bian. "Cyr61 Alleviates Cholangitis by Inhibiting Cytotoxic Effects of CD8+ T Cells on Biliary Epithelial Cells", Current Medical Science, 2021 16 words — < 1%
Crossref

32 www.ncbi.nlm.nih.gov 16 words — < 1%
Internet

33   Hyungjun Yang, Hyun-Jeong Ko, Jin-Young Yang, Jae-Jin Kim et al. "Interleukin-1 Promotes Coagulation, Which Is Necessary for Protective Immunity in the Lung Against Streptococcus pneumoniae Infection", The Journal of Infectious Diseases, 2013   15 words — < 1%
Crossref

34   dspace.cuni.cz   15 words — < 1%
Internet

35   www.hindawi.com   15 words — < 1%
Internet

36   S. Bentz. "Lack of transketolase-like (TKTL) 1 aggravates murine experimental colitis", AJP Gastrointestinal and Liver Physiology, 01/13/2011   14 words — < 1%
Crossref

37   pre-med.jumedicine.com   14 words — < 1%
Internet

38   Gang Wang, Wei Du, Lingyi Che, Xianzheng Gao, Ruihua Zhao, Juan Duan, Zhuoyu Gu, Qian Ma. "High Expression of PLAGL2 is Associated With Poor Prognosis in High-Grade Glioma", Frontiers in Genetics, 2022   13 words — < 1%
Crossref

39   Lin-Yan Huang, Qing He, Si-Jia Liang, Ying-Xue Su et al. "ClC-3 chloride channel/antiporter defect contributes to inflammatory bowel disease in humans and mice", Gut, 2014   13 words — < 1%
Crossref

40   Stroo, Ingrid, Nike Claessen, Gwendoline J. D. Teske, Loes M. Butter, Sandrine Florquin, and Jaklien C. Leemans. "Deficiency for the Chemokine Monocyte   13 words — < 1%

Chemoattractant Protein-1 Aggravates Tubular Damage after Renal Ischemia/Reperfusion Injury", PLoS ONE, 2015.
Crossref

41   fedetd.mis.nsysu.edu.tw
      Internet
      13 words — < 1%

42   www.fasebj.org
      Internet
      13 words — < 1%

43   Lindsay, J.O.. "Rectal administration of an adenoviral vector encoding IL-10 induces colonic IL-10 release with minimal anti-adenoviral response", Gastroenterology, 200104
      Crossref
      12 words — < 1%

44   Wenji Li, Yue Guo, Chengyue Zhang, Renyi Wu, Anne Yuqing Yang, John Gaspar, Ah-Ng Tony Kong. "Dietary Phytochemicals and Cancer Chemoprevention: A Perspective on Oxidative Stress, Inflammation, and Epigenetics", Chemical Research in Toxicology, 2016
      Crossref
      12 words — < 1%

45   discovery.ucl.ac.uk
      Internet
      12 words — < 1%

46   www.ecerm.org
      Internet
      12 words — < 1%

47   C-F Hung. "Control of human mesothelin-expressing tumors by DNA vaccines", Gene Therapy, 08/2007
      Crossref
      11 words — < 1%

48   Thomas A. Ullman, Steven H. Itzkowitz. "Intestinal Inflammation and Cancer", Gastroenterology, 2011
      Crossref
      11 words — < 1%

49 bmccancer.biomedcentral.com
Internet

11 words — < 1%

50 d-nb.info
Internet

11 words — < 1%

51 pubmed.ncbi.nlm.nih.gov
Internet

11 words — < 1%

52 Danielle Stanton-Turcotte, Karolynn Hsu, Samantha A Moore, Makiko Yamada, James P Fawcett, Angelo Iulianella. "Mllt11 regulates the migration and neurite outgrowth of cortical projection neurons during development", Cold Spring Harbor Laboratory, 2021
Crossref Posted Content

10 words — < 1%

53 www.mdpi.com
Internet

10 words — < 1%

54 www.researchsquare.com
Internet

10 words — < 1%

55 Deng, Que, Hongyu Chen, Yanjun Liu, Fengjun Xiao, Liang Guo, Dan Liu, Xiang Cheng, Min Zhao, Xiaomeng Wang, Shuai Xie, Siyong Qi, Zhaoyang Yin, Jiangping Gao, Xintian Chen, Jiangong Wang, Ning Guo, Yuanfang Ma, and Ming Shi. "Psychological stress promotes neutrophil infiltration in colon tissue through adrenergic signaling in DSS-induced colitis model", Brain Behavior and Immunity, 2016.
Crossref

9 words — < 1%

56 F. Chang. "Tumor Necrosis Factor Receptor 1 functions as a tumor suppressor", AJP Gastrointestinal and Liver Physiology, 11/03/2011
Crossref

9 words — < 1%

57   Jeremy Denizot. "Adherent-invasive Escherichia coli induce claudin-2 expression and barrier defect in CEABAC10 mice and Crohn's disease patients", Inflammatory Bowel Diseases, 02/2012
Crossref

9 words — < 1%

58   Lauren Van Der Kraak, David Langlais, Serge Jothy, Nicole Beauchemin, Philippe Gros. "Mapping hyper-susceptibility to colitis-associated colorectal cancer in FVB/NJ mice", Mammalian Genome, 2016
Crossref

9 words — < 1%

59   Ran Zhao, Yukun Liu, Chunchun Wu, Mengna Li et al. "BRD7 Promotes Cell Proliferation and Tumor Growth Through Stabilization of c-Myc in Colorectal Cancer", Frontiers in Cell and Developmental Biology, 2021
Crossref

9 words — < 1%

60   Samuel Asfaha, Alexander N. Dubeykovskiy, Hiroyuki Tomita, Xiangdong Yang et al. "Mice That Express Human Interleukin-8 Have Increased Mobilization of Immature Myeloid Cells, Which Exacerbates Inflammation and Accelerates Colon Carcinogenesis", Gastroenterology, 2013
Crossref

9 words — < 1%

61   Saxena, A.. "Adiponectin deficiency: Role in chronic inflammation induced colon cancer", BBA - Molecular Basis of Disease, 201204
Crossref

9 words — < 1%

62   mediatum.ub.tum.de
Internet

9 words — < 1%

63   molmed.biomedcentral.com
Internet

9 words — < 1%

57   ri.conicet.gov.ar

Internet

9 words — < 1%

65 www.hilarispublisher.com
Internet

9 words — < 1%

66 www.science.gov
Internet

9 words — < 1%

67 "Abstracts of the 25th Annual Conference of APASL, February 20–24, 2016, Tokyo, Japan", Hepatology International, 2016
Crossref

8 words — < 1%

68 "P008. IL-34 antibody ameliorates experimental Colitis by alternating IL-12p40 expression in macrophages", Journal of Crohn s and Colitis, 2015.
Crossref

8 words — < 1%

69 Aditya Ambade, Abhishek Satishchandran, Benedek Gyongyosi, Patrick Lowe, Gyongyi Szabo. "Adult mouse model of early hepatocellular carcinoma promoted by alcoholic liver disease", World Journal of Gastroenterology, 2016
Crossref

8 words — < 1%

70 Chunmei Ma, Dongxue Yang, Bingwei Wang, Chunyan Wu, Yuqing Wu, Sheng Li, Xue Liu, Kara Lassen, Lue Dai, Shuo Yang. "Gasdermin D in macrophages restrains colitis by controlling cGAS-mediated inflammation", Science Advances, 2020
Crossref

8 words — < 1%

71 Ito, R.. "Involvement of IL-17A in the pathogenesis of DSS-induced colitis in mice", Biochemical and Biophysical Research Communications, 20081205
Crossref

8 words — < 1%

72 Laëtitia Kermarrec, Nour Eissa, Hongxing Wang, Kunal Kapoor et al. " Semaphorin‐3E attenuates intestinal inflammation through the regulation of the communication between splenic CD11C and CD4 CD25 T‐cells ", British Journal of Pharmacology, 2019
Crossref

8 words — < 1%

73 Neng Yang, Zongling Xia, Naiyuan Shao, Bowen Li, Lian Xue, Ya Peng, Feng Zhi, Yilin Yang. "Carnosic acid prevents dextran sulfate sodium-induced acute colitis associated with the regulation of the Keap1/Nrf2 pathway", Scientific Reports, 2017
Crossref

8 words — < 1%

74 Ramadass, Satiesh Kumar, Sathiamurthi Perumal, Sugin Lal Jabaris, and Balaraman Madhan. "Preparation and evaluation of mesalamine collagen in situ rectal gel: A novel therapeutic approach for treating ulcerative colitis", European Journal of Pharmaceutical Sciences, 2013.
Crossref

8 words — < 1%

75 Ray, Anita L., Eliseo F. Castillo, Katherine T. Morris, Robert A Nofchissey, Lea L Weston, Von G. Samedi, Joshua A. Hanson, Matthias Gaestel, Irina V. Pinchuk, and Ellen J. Beswick. "Blockade of MK2 is protective in inflammation-associated colorectal cancer development : MK2 blockade is protective in mouse colorectal cancer", International Journal of Cancer, 2015.
Crossref

8 words — < 1%

76 Sterner-Collingwood, T, E Smirnova, R Annan, and A Tsygankov. "Tula protein as a novel factor in the development and therapy of Crohn's Disease : P-0018", Inflammatory Bowel Diseases, 2007.
Crossref

8 words — < 1%

77   Tatsuya Ohkawara, Keiichi Mitsuyama, Hiroshi Takeda, Masahiro Asaka, Yoshihide Fujiyama, Jun Nishihira. "Lack of macrophage migration inhibitory factor suppresses innate immune response in murine dextran sulfate sodium-induced colitis", Scandinavian Journal of Gastroenterology, 2009
Crossref

8 words — < 1%

78   Yunwei Lou, Honghong Sun, Samantha Morrissey, Thomas Porturas, Suxia Liu, Xianxin Hua, Youhai H. Chen. "Critical Roles of TIPE2 Protein in Murine Experimental Colitis", The Journal of Immunology, 2014
Crossref

8 words — < 1%

79   obgyn.pericles-prod.literatumonline.com
Internet

8 words — < 1%

80   Akihiro Araki, Takanori Kanai, Takahiro Ishikura, Shin Makita et al. "MyD88-deficient mice develop severe intestinal inflammation in dextran sodium sulfate colitis", Journal of Gastroenterology, 2005
Crossref

7 words — < 1%

81   P. P. Nawroth. "RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis", Carcinogenesis, 03/13/2008
Crossref

7 words — < 1%

82   S.-J. Koh. "Fluoxetine inhibits NF- B signaling in intestinal epithelial cells, and ameliorates experimental colitis and colitis-associated colon cancer in mice", AJP Gastrointestinal and Liver Physiology, 03/24/2011
Crossref

7 words — < 1%

83   Sheng-Tao Cheng, Hua Tang, Ji-Hua Ren, Xiang Chen, Ai-Long Huang, Juan Chen. "Interleukin-34

7 words — < 1%

inhibits hepatitis B virus replication in vitro and in vivo", PLOS ONE, 2017
Crossref

84   Thomas R Berton, David L Mitchell, Ruifeng Guo, David G Johnson. "Regulation of epidermal apoptosis and DNA repair by E2F1 in response to ultraviolet B radiation", Oncogene, 2005
Crossref
   7 words — < 1%

85   Wei Qiu. "PUMA-mediated intestinal epithelial apoptosis contributes to ulcerative colitis in humans and mice", Journal of Clinical Investigation, 04/01/2011
Crossref
   7 words — < 1%

86   Zaki, Md.H.. "The NLRP3 Inflammasome Protects against Loss of Epithelial Integrity and Mortality during Experimental Colitis", Immunity, 20100326
Crossref
   7 words — < 1%

87   Long, Tiha M., Arindam Chakrabarti, Heather J. Ezelle, Sarah E. Brennan-Laun, Jean-Pierre Raufman, Irina Polyakova, Robert H. Silverman, and Bret A. Hassel. "RNase-L Deficiency Exacerbates Experimental Colitis and Colitis-associated Cancer :", Inflammatory Bowel Diseases, 2013.
Crossref
   6 words — < 1%

88   Niranjan G. Kotla, Isma Liza Mohd Isa, Swetha Rasala, Secil Demir et al. "Modulation of Gut Barrier Functions in Ulcerative Colitis by Hyaluronic Acid System", Advanced Science, 2021
Crossref
   6 words — < 1%

89   Y. Nakamichi, T. Mizoguchi, A. Arai, Y. Kobayashi et al. "Spleen serves as a reservoir of osteoclast precursors through vitamin D-induced IL-34 expression in osteopetrotic op/op mice", Proceedings of the National
   6 words — < 1%

Academy of Sciences, 2012
Crossref

90   Yi Shen, Jun Ma, Ruilan Yan, Hongyan Ling et al.
"Impaired Self-Renewal and Increased Colitis and
Dysplastic Lesions in Colonic Mucosa of AKR1B8-Deficient
Mice", Clinical Cancer Research, 2015
Crossref

6 words — < 1%

EXCLUDE QUOTES   OFF   EXCLUDE SOURCES   OFF

EXCLUDE BIBLIOGRAPHY   OFF   EXCLUDE MATCHES   OFF